
35-43. Couturier, Matthieu. A Case Study of Vioxx Using STAMP. Master’s thesis, Technology and Policy
Program, Engineering Systems Division, MIT, June 2010.
https://dspace.mit.edu/bitstream/handle/1721.1/59557/668214373-MIT.pdf?sequence=2

Abramas, Thomas W. (2001). Warning Letter. 9. Retrieved from
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Enfor cementActivitiesbyFDA/WarningLettersandNoticeofViolationLetterstoPharmaceuticalCo mpanies/UCM166383.pdf
ACRO (2007). The Role of CROs in Clinical Trials Retrieved August 26, 2009, 2009, from
http://www.acrohealth.org/pdfs/The%20Role%20of%20CROs.pdf
Anderson, Geoffrey M., Juurlink, David, & Detsky, Allan S. (2008). Newly Approved Does Not Always Mean New and Improved. JAMA, 299(13), 1598-1600.
Anderson, William B. (2001). The media battle between Celebrex and Vioxx: influencing media coverage but not content. Public Relations Review, 27(4), 449-460.
Angell, Marcia M.D. (2005). The Truth About the Drug Companies: How they deceive us and what to do about it: Random House.

Angell, Marcia M.D. (2006, June 8, 2006). Your Dangerous Drugstore. The New York Review of Books, 53.

Avorn, Jerry (2006). Dangerous Deception -- Hiding the Evidence of Adverse Drug Effects. N Engl J Med, 355(21), 2169-2171.

Avorn, Jerry (2007). Paying for Drug Approvals -- Who's Using Whom? N Engl J Med, 356(17), 1697-1700.

Baciu, Alina, Stratton, Kathleen R, & Burke, Sheila P (2007). The future of drug safety : promoting and protecting the health of the public (No. 9780309103046 0309103045). Washington, D.C.: Institute Of Medicine.

BBC (2005, January 25, 2005). Arthritis drug heart harm claim. BBC. from http://news.bbc.co.uk/2/hi/health/4203437.stm

Berenson, Alex (2005, April 24, 2005). Evidence in Vioxx Suits Shows Intervention by Merck Officials. The New York Times. from http://www.nytimes.com/2005/04/24/business/24drug.html

Berenson, Alex, Harris, Gardiner, Meier, Barry, & Pollack, Andrew (2004, November 14, 2004). Despite Warnings, Drug Giant Took Long Path to Vioxx Recall. The New York Times. Retrieved April 8, 2010, from http://www.nytimes.com/2004/11/14/business/14merck.html

Bhandari, Mohit, Busse, Jason W., Jackowski, Dianne, Montori, Victor M., Schunemann, Holger, Sprague, Sheila, et al. (2004). Association between industry funding and statistically significant pro-industry findings in medical and surgical randomized trials. CMAJ, 170(4), 477-480.

Bodenheimer, Thomas (2000). Uneasy Alliance -- Clinical Investigators and the Pharmaceutical Industry. N Engl J Med, 342(20), 1539-1544.

Bombardier, Claire, Laine, Loren, Reicin, Alise, Shapiro, Deborah, Burgos-Vargas, Ruben, Davis, Barry, et al. (2000). Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid Arthritis. N Engl J Med, 343(21), 1520-1528.

Cauchon, Denis (2000, September 25, 2000). FDA advisers tied to industry. USA TODAY. Retrieved August 28, 2009, from http://www.gene.ch/gentech/2000/Sep/msg00092.html

Congress (2007). Public Law 110–85. Retrieved December 18, 2008. from http://frwebgate.access.gpo.gov/cgi- bin/getdoc.cgi?dbname=110_cong_public_laws&docid=f:publ085.110.pdf.
          
Conko, Gregory (2008, August 23, 2008). Sick Patients Need Cutting-Edge Drugs. The Wall Street Journal. Retrieved January 10, 2009, from http://online.wsj.com/article/SB121944789005365195.html

Debabrata, Mukherjee, & Eric, J. Topol (2003). Pharmaceutical advertising versus research spending: are profits more important than patients? American heart journal, 146(4), 563- 564.

Dekker, Sidney (2007). Just culture : balancing safety and accountability. Aldershot, England; Burlington, VT: Ashgate.

Drinkard, Jim (2005, April 25, 2005). Drugmakers go furthest to sway Congress. USA TODAY. from http://www.usatoday.com/money/industries/health/drugs/2005-04-25-drug-lobby- cover_x.htm

FDA (2002). The FDA's Drug Review Process: Ensuring Drugs Are Safe and Effective. FDA Consumer magazine, July-August 2002 Issue.

FDA (2003a, April 25, 2008). Postmarketing Study Commitments: Introduction Retrieved January 10, 2009, 2009, from http://www.fda.gov/CDER/pmc/default.htm

FDA (2003b). Prescription Drug User Fees -- Overview Retrieved January 9, 2009, 2009, from
http://www.fda.gov/oc/pdufa/overview.html

FDA (2004, November 2, 2006). Drugs@FDA Instructions: Health Information Retrieved January 10, 2009, 2009, from http://www.fda.gov/cder/drugsatfda/instructionsHealth.htm

FDA (2006). Information Sheet Guidance For IRBs, Clinical Investigators, and Sponsors (Guidance Sheet): Food and Drug Administration.

FDA (2007). FDA’s Response to the Institute of Medicine’s 2006 Report.: U.S. Department of Health and Human Services, Food and Drug Administration (FDA).

FDA (2008). Justification of Estimates for Appropriations Committees. Retrieved January 7, 2009. from http://www.fda.gov/oc/oms/ofm/budget/2009/TOC.htm.

FDA (2009a). 21CFR314.80. Retrieved April 8, 2010. from http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=314.80.

FDA (2009b). Adverse Event Reporting System (AERS) Retrieved November 9, 2009, 2009, from
http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/default.htm

FDA (2009c). Advisory Committees Retrieved Augsut 27, 2009, 2009, from
http://www.fda.gov/AdvisoryCommittees/default.htm

FDA (2009d, June 18, 2009). FDA Glossary of Terms Retrieved August 29, 2009, 2009, from
http://www.fda.gov/Drugs/InformationOnDrugs/ucm079436.htm

FDA (2009e). FDA Overview Retrieved January 7, 2009, 2009, from
http://www.fda.gov/oc/opacom/fda101/sld001.html

FDA (2009f). History Retrieved November 1, 2009, 2009, from
http://www.fda.gov/AboutFDA/WhatWeDo/History/default.htm

FDA (2009g, July 13, 2009). Legislation Retrieved August 28, 2009, 2009, from
http://www.fda.gov/RegulatoryInformation/Legislation/default.htm

FDA (2009h, July 1t6, 2009). New Drug Application (NDA) Retrieved August 27, 2009, 2009, from
http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandAp proved/ApprovalApplications/NewDrugApplicationNDA/default.htm
                 
FDA (2009i, July 23, 2009). Office of Surveillance and Epidemiology Retrieved August 27, 2009, 2009, from http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm106491.htm

FDA (2009j). Summary of FDA's FY 2009 Budget Retrieved January 7, 2009, 2009, from
http://www.fda.gov/oc/factsheets/budget2009.html

FDA (2010, 02/01/2010 ). Advisory Committees Retrieved February 2, 2010, 2010, from
http://www.fda.gov/AdvisoryCommittees/default.htm

Fielder, J. H. (2008). The Vioxx debacle revisited [Issues in Ethics]. Engineering in Medicine and Biology Magazine, IEEE, 27(4), 106-109.

Finkelstein, Stan N., & Temin, Peter (2008). Reasonable Rx: Solving the Drug Price Crisis: FT Press.

Flanagin, Annette, Carey, Lisa A., Fontanarosa, Phil B., Phillips, Stephanie G., Pace, Brian P., Lundberg, George D., et al. (1998). Prevalence of Articles With Honorary Authors and Ghost Authors in Peer-Reviewed Medical Journals. JAMA, 280(3), 222-224.

Forrester, Jay W. (2000). From the Ranch to System Dynamics: An Autobiography. In Arthur G. Bedeian (Ed.), Management Laureats: A Collection of Autobiographical Essays, Vol 1. Friedberg, Mark, Saffran, Bernard, Stinson, Tammy J., Nelson, Wendy, & Bennett, Charles L. (1999). Evaluation of Conflict of Interest in Economic Analyses of New Drugs Used in Oncology. JAMA, 282(15), 1453-1457.

GAO (2006). Drug Safety: Improvement Needed in FDA's Postmarket Decision-making and Oversight Process: United States Government Accountability Office.

GAO (2008). Prescription Drugs: FDA's Oversight of the Promotion of Drugs for Off-Label Uses: United States Government Accountability Office.

Garfield, Bob (2009, May 29, 2009). Peer Pressure. NPR. Retrieved May 4, 2009, from
http://www.onthemedia.org/transcripts/2009/05/29/04
Testimony of David J. Graham, MD, MPH, November 18, 2004, Senate 9 (2004).

Graham, David J., Campen, David, Hui, Rita, Spence, Michele, Cheetham, Craig, Levy, Gerald, et al. (2005). Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti- inflammatory drugs: nested case-control study. The Lancet, 365(9458), 475-481.

Harris, Gardiner (2006, September 23, 2006). Study Condemns F.D.A.'s Handling of Drug Safety. The New York Times. from http://www.nytimes.com/2006/09/23/health/policy/23fda.html

Harris, Gardiner (2008, November 2, 2008). The Safety Gap. The New York Times. from http://www.nytimes.com/2008/11/02/magazine/02fda-t.html?pagewanted=print

Harris, Gardiner, & Berenson, Alex (2005, February 25, 2005). 10 Voters on Panel Backing Pain Pills Had Industry Ties. The New York Times. from http://www.nytimes.com/2005/02/25/politics/25fda.html

Harris, Gardiner, & Bogdanich, Walt (2008, February 15, 2008). F.D.A. Broke Its Rules by Not Inspecting Chinese Plant With Problem Drug. The New York Times. from http://www.nytimes.com/2008/02/15/washington/15fda.html

Hill, Kevin P., Ross, Joseph S., Egilman, David S., & Krumholz, Harlan M. (2008). The ADVANTAGE Seeding Trial: A Review of Internal Documents. Ann Intern Med, 149(4), 251-258.

Institute of Medicine, Baciu, Alina, Stratton, Kathleen R, & Burke, Sheila P (2007). The future of drug safety : promoting and protecting the health of the public. Washington, D.C.: National Academies Press.
        
Jüni, Peter, Nartey, Linda, Reichenbach, Stephan, Sterchi, Rebekka, Dieppe, Paul A., & Egger, Matthias (2004). Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. The Lancet, 364(9450), 2021-2029.

Kaiser Foundation (2009). Medicare: A Primer. 25. Retrieved from
http://www.kff.org/medicare/upload/7615-02.pdf

Sandra Kweder, M.D. Testimony on November 18, 2004, United States Senate (2004).

Leveson, Nancy G. (2003). System Safety Engineering: Back To The Future.

Leveson, Nancy G. (2004). A new accident model for engineering safer systems. Safety Science, 42(4), 237-270.

Leveson, Nancy G. (2005). Safety in Integrated Systems Health Engineering and Management.
Paper presented at the NASA Ames Integrated System Health Engineering and Management Forum. from http://ti.arc.nasa.gov/projects/ishem/Papers/Leveson_Safety.doc

Leveson, Nancy G. (2010). Applying systems thinking to analyze and learn from events. Safety Science.

Levinson, Daniel R. (2007). The Food and Drug Administration's Oversight of Clinical Trials. 41. Retrieved from http://www.oig.hhs.gov/oei/reports/oei-01-06-00160.pdf

Lexchin, Joel, & Light, Donald W (2006). Commercial influence and the content of medical journals. BMJ, 332(7555), 1444-1447.

Martin, John S. Jr. (2006). Report of The Honorable John S. Martin, Jr. to the Special Committee of the Board of Directors of Merck & Co., Inc. Concerning the Conduct of Senior Management in the Development and Marketing of Vioxx.

McClellan, Mark (2007). Drug Safety Reform at the FDA -- Pendulum Swing or Systematic Improvement? N Engl J Med, 356(17), 1700-1702.

Merck (2001). Dodge Ball Vioxx. 14. Retrieved from http://dida.library.ucsf.edu/pdf/oxx10p10 Merck (2002). VIOXX (rofecoxib tablets and oral suspension). 28. Retrieved from
http://www.fda.gov/cder/foi/label/2004/21647_vioxx_lbl.pdf

Merck (2008a). Fact Sheet Retrieved December 20, 2008, 2008, from
http://www.merck.com/newsroom/fact_sheet/

Merck (2008b). History of Merck Retrieved December 20, 2008, from
http://www.msd.com.hk/about_us/e_history_of_merck.html

Merck (2008c). Mission Statement Retrieved December 20, 2008, 2008, from
http://www.merck.com/about/mission.html

Mintzes, Barbara, Barer, Morris L., Kravitz, Richard L., Bassett, Ken, Lexchin, Joel, Kazanjian, Arminee, et al. (2003). How does direct-to-consumer advertising (DTCA) affect prescribing? A survey in primary care environments with and without legal DTCA. CMAJ, 169(5), 405-412.

Moynihan, Ray (2008). Doctors' education: the invisible influence of drug company sponsorship. BMJ, 336(7641), 416-417.

Mukherjee, Debabrata, Nissen, Steven E., & Topol, Eric J. (2001). Risk of Cardiovascular Events Associated With Selective COX-2 Inhibitors. JAMA, 286(8), 954-959.

Okie, Susan (2005). What Ails the FDA? N Engl J Med, 352(11), 1063-1066.

OpenSecrets.org (2009). Top Industries giving to Members of Congress, 2000 Cycle Retrieved August 28, 2008, 2009, from
http://www.opensecrets.org/industries/mems.php?party=A&cycle=2000
         
Pear, Robert (2003, June 1, 2003). Drug Companies Increase Spending on Efforts to Lobby Congress and Governments The New York Times. Retrieved January 9, 2009, from http://query.nytimes.com/gst/fullpage.html?res=9E06E7DF1530F932A35755C0A9659C 8B63&scp=1&sq=Drug%20Companies%20Increase%20Spending%20on%20Efforts%2 0to%20Lobby%20Congress%20and%20Governments%20&st=cse

Pollack, Andrew (2008, November 28, 2008). The Minimal Impact of a Big Hypertension Study. The New York Times. from http://www.nytimes.com/2008/11/28/business/28govtest.html

Prosser, Helen, Almond, Solomon, & Walley, Tom (2003). Influences on GPs' decision to prescribe new drugs--the importance of who says what. Fam. Pract., 20(1), 61-68.

Psaty, Bruce M., & Charo, R. Alta (2007). FDA Responds to Institute of Medicine Drug Safety Recommendations--In Part. JAMA, 297(17), 1917-1920.

Psaty, Bruce M., & Korn, David (2007). Congress Responds to the IOM Drug Safety Report In Full. JAMA, 298(18), 2185-2187.

Psaty, Bruce M., & Kronmal, Richard A. (2008). Reporting Mortality Findings in Trials of Rofecoxib for Alzheimer Disease or Cognitive Impairment: A Case Study Based on Documents From Rofecoxib Litigation. JAMA, 299(15), 1813-1817.

Rasmussen, Jens (1997). Risk management in a dynamic society: a modelling problem. Safety Science, 27(2-3), 183-213.

Relman, Arnold S. (2001). Separating Continuing Medical Education From Pharmaceutical Marketing. JAMA, 285(15), 2009-2012.

Rennie, Drummond (1997). Thyroid Storm. JAMA, 277(15), 1238-1243.

Reuters (2005, August 19, 2005). A Time Line of Vioxx. The New York Times. from
http://www.nytimes.com/2005/08/19/business/19vioxx.timeline.html?ref=business

Rosen, Clifford J. (2007). The Rosiglitazone Story -- Lessons from an FDA Advisory Committee Meeting. N Engl J Med, 357(9), 844-846.

Ross, Joseph S., Hill, Kevin P., Egilman, David S., & Krumholz, Harlan M. (2008). Guest Authorship and Ghostwriting in Publications Related to Rofecoxib: A Case Study of Industry Documents From Rofecoxib Litigation. JAMA, 299(15), 1800-1812.

Schultz, William B. (2007). Bolstering the FDA's Drug-Safety Authority. N Engl J Med, 357(22), 2217-2219.

Shook, David (2000, MAY 31, 2000 ). Beware of Merck's Coming Patent Headache. BusinessWeek. from
http://www.businessweek.com/bwdaily/dnflash/may2000/sw00531.htm

Singer, Natasha (2009, May 14, 2009). Merck Paid for Medical 'Journal' Without Disclosure. The New York Times. Retrieved June 4, 2009, from http://www.nytimes.com/2009/05/14/business/14vioxxside.html

Smith, Richard (2003). Medical journals and pharmaceutical companies: uneasy bedfellows. BMJ, 326(7400), 1202-1205.

Smith, Sheila Weiss (2007). Sidelining Safety -- The FDA's Inadequate Response to the IOM. N Engl J Med, 357(10), 960-963.

Sofer, Gideon J. (2008, December 30, 2008). The FDA Is Killing Crohn's Patients. The Wall Street Journal. Retrieved January 10, 2009

Sterman, John D. (2000). Business Dynamics: Systems Thinking and Modeling for a Complex World: McGraw-Hill

Sterman, John D. (2002). All models are wrong: reflections on becoming a systems scientist. System Dynamics Review (Wiley), 18(4), 501-531.
       
Stern, Jerome M., & Simes, R. John (1997). Publication bias: evidence of delayed publication in a cohort study of clinical research projects. BMJ, 315(7109), 640-645.

Suydam, Linda A. (2000). FDA Advisory Committes (Statement): The House Committee on Government Reform.

Swann, John P. (2009). History of the FDA Retrieved January 7, 2009, 2009, from
http://www.fda.gov/oc/history/historyoffda/default.htm

Targum, Shari (2001). Consultation NDA 21-042, S-007 - Review of cardiovascular safety database. Retrieved Augsust 27, 2009. from http://www.fda.gov/ohrms/dockets/ac/01/briefing/3677b2_06_cardio.pdf.

Topol, Eric J. (2004). Failing the Public Health -- Rofecoxib, Merck, and the FDA. N Engl J Med, 351(17), 1707-1709.

Wadhwani, Vikram (2004). Vioxx: Merck in Big Pain: Forst & Sullivan.

Waxman, Henry A. (2005a). The Lessons of Vioxx -- Drug Safety and Sales. N Engl J Med, 352(25), 2576-2578.

Waxman, Henry A. (2005b). The Marketing of Vioxx to Physicians. from
http://oversight.house.gov/documents/20050505114932-41272.pdf.

Wazana, Ashley (2000). Physicians and the Pharmaceutical Industry: Is a Gift Ever Just a Gift? JAMA, 283(3), 373-380.

Woodcock, Janet (2000). Drug-related Adverse Events: Senate Committee on Health, Education,
Labor, and Pensions.
